Ascendis Pharma A/S (ASND) NASDAQ
213.23
+7.42(+3.61%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
213.23
+7.42(+3.61%)
Currency In USD
| Previous Close | 205.81 |
| Open | 207.33 |
| Day High | 215.44 |
| Day Low | 204.3 |
| 52-Week High | 250.74 |
| 52-Week Low | 160.86 |
| Volume | 461,601 |
| Average Volume | 640,012 |
| Market Cap | 13.17B |
| PE | 24.45 |
| EPS | 8.72 |
| Moving Average 50 Days | 232.33 |
| Moving Average 200 Days | 216.74 |
| Change | 7.42 |
Ascendis Pharma to Participate in the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Mar 02, 2026 1:43 PM GMT
COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 20
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
GlobeNewswire Inc.
Feb 27, 2026 10:57 PM GMT
The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease Priority Review Voucher granted in co
Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026
GlobeNewswire Inc.
Feb 04, 2026 9:01 PM GMT
COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11, 2026, after the close of the U.S.